Oculis Holding AG

OCSAW

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Perceptive Advisors

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Perceptive AdvisorsNEWFeb 17, 2026

Shares: 493,827Value: $9.9M

# Signal Note: Perceptive Advisors Initiates Oculis Position Perceptive's $9.9M entry into Oculis suggests confidence in the Swiss biotech's clinical-stage ophthalmology pipeline, likely anchored on OCL01 (suprachoroidal CsA) for dry eye disease—a large, underserved market where the company has demonstrated tolerability in early studies. The timing likely reflects positioning ahead of upcoming Phase 2b readout or IND-enabling data that could validate the suprachoroidal delivery approach as differentiated versus existing topical therapies. Edelman's clinical-stage expertise indicates focus on robust efficacy/safety inflection points rather than speculative plays.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

IVVD1 fund KRYS1 fund BLLN1 fund DXCM1 fund ENSCW1 fund GRAL1 fund IKT1 fund AMLX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: